Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Methocarbamol (AHR 85) 是口服有效的中枢肌肉松弛剂,可阻断肌肉Nav1.4通道,阻断作用具有可逆性。Methocarbamol 具有用于肌肉痉挛和疼痛综合症研究的潜力。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
25 mg | ¥ 278 | 现货 | ||
50 mg | ¥ 418 | 现货 | ||
100 mg | ¥ 614 | 现货 | ||
200 mg | ¥ 864 | 现货 | ||
500 mg | ¥ 1,266 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 221 | 现货 |
产品描述 | Methocarbamol (AHR 85) is a centrally acting muscle relaxant whose mode of action has not been established. It is used as an adjunct in the symptomatic treatment of musculoskeletal conditions associated with painful muscle spasm. |
体外活性 | Methocarbamol is metabolized via dealkylation and hydroxylation followed by conjugation to form both glucuronides and sulfates. [1] |
体内活性 | Methocarbamol results in a median terminal half-life, mean transit time, mean absorption time, and apparent oral clearance of 2.89 hours, 2.67 hours, 0.410 hours, and 16.5 mL/min/kg in the horse. Methocarbamol is rapidly absorbed and extensively metabolized after oral administration to horses as indicated by a short absorption time and modest systemic bioavailability of 54.4% in the horse. [1] Methocarbamol is a centrally acting muscle relaxant available in both IV and oral forms in cats. [2] Methocarbamol (100 mg/kg) does not change the heart rate, cardiac output, mean pulmonary arterial blood pressure, systolic, diastolic and mean aortic blood pressure, respiratory rate and arterial blood gases, but mild to moderate depression is observed in five of eight horses administered i.v. Methocarbamol, and in all horses administered oral Methocarbamol. Plasma Methocarbamol concentration declines very rapidly during the initial or rapid disposition phase after i.v. administration; the terminal elimination half-life ranged from 59 minutes to 90 minutes in horse. Peak plasma Methocarbamol concentrations following oral administration occur within 15 to 45 minutes in horse. [3] |
别名 | Lumirelax, 美索巴莫, Metocarbamol, AHR 85, Robaxin |
分子量 | 241.24 |
分子式 | C11H15NO5 |
CAS No. | 532-03-6 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 45 mg/mL (186.5 mM)
Ethanol: 45 mg/mL (186.5 mM)
H2O: 2 mg/mL (8.29 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO / Ethanol / H2O | 1 mM | 4.1452 mL | 20.7262 mL | 41.4525 mL | 103.6312 mL |
5 mM | 0.829 mL | 4.1452 mL | 8.2905 mL | 20.7262 mL | |
DMSO / Ethanol | 10 mM | 0.4145 mL | 2.0726 mL | 4.1452 mL | 10.3631 mL |
20 mM | 0.2073 mL | 1.0363 mL | 2.0726 mL | 5.1816 mL | |
50 mM | 0.0829 mL | 0.4145 mL | 0.829 mL | 2.0726 mL | |
100 mM | 0.0415 mL | 0.2073 mL | 0.4145 mL | 1.0363 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Methocarbamol 532-03-6 Membrane transporter/Ion channel Metabolism Sodium Channel Carbonic Anhydrase muscle relaxant Lumirelax inhibit 美索巴莫 Na channels central Inhibitor AHR-85 Metocarbamol AHR85 AHR 85 Na+ channels Robaxin musculoskeletal inhibitor